Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO), Phibro Animal Health (PAHC) and Unicycive Therapeutics (UNCY)
Analysts have provided new ratings for several healthcare companies. Stifel Nicolaus analyst Daniel Arias maintained a Buy rating on Thermo Fisher (TMO) with a $700.00 price target, suggesting a strong upside. Bank of America Securities analyst Michael Ryskin maintained a Sell rating on Phibro Animal Health (PAHC), while Noble Financial's Robert LeBoyer reiterated a Buy rating on Unicycive Therapeutics (UNCY) with a significant price target of $60.00, implying a substantial upside.
Maravai LifeSciences Holdings (NASDAQ:MRVI shareholders incur further losses as stock declines 11% this week, taking five-year losses to 90%
Maravai LifeSciences Holdings (NASDAQ:MRVI) has seen its stock price drop by 90% over the last five years, including an 11% decline this past week and 32% over the last twelve months. The company is not currently profitable, and its revenue has shrunk by 21% per year over the last five years. Despite the poor financial performance, there has been some significant insider buying in the last three months, which could be a positive sign.
MRVI SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Maravai LifeSciences Holdings, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) on behalf of investors who purchased shares between August 7, 2024, and February 24, 2025. The lawsuit alleges that Maravai made false and misleading statements regarding its revenue recognition, internal controls, and goodwill, leading to an overstatement of its financial prospects. Shareholders with losses during this period have until May 5, 2025, to seek appointment as lead plaintiff.
Maravai ALERT: Bragar Eagel & Squire, P.C. is Investigating Maravai LifeSciences Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) on behalf of long-term stockholders. The investigation follows a class action complaint filed after Maravai announced errors in revenue recognition, a material weakness in internal controls, and a potential non-cash impairment charge related to a past acquisition, causing a significant drop in share price. The law firm is encouraging affected investors to contact them for more information.
A US$75m Market Cap Boost Pleasing ToMaravai LifeSciences Holdings Insiders
Maravai LifeSciences Holdings (NASDAQ:MRVI) experienced a 16% stock increase last week, adding US$75m to its market capitalization, which was pleasing for insiders who bought shares over the past year. Insiders, notably CEO Bernd Brust, collectively purchased US$1.9m worth of shares, indicating a positive outlook although the company did not make a profit in the last year. Insider ownership stands at 2.5%, aligning management's interests with smaller shareholders.
MRVI INVESTOR ALERT: Kirby McInerney LLP Reminds Maravai Lifesciences Holdings, Inc. Investors of Looming Lead Plaintiff Deadline in Class Action Lawsuit
Kirby McInerney LLP is reminding investors of Maravai Lifesciences Holdings, Inc. (NASDAQ:MRVI) that the lead plaintiff deadline for a federal securities class action lawsuit is May 5, 2025. The lawsuit alleges that Maravai failed to disclose inadequate internal controls over revenue recognition and an overstatement of goodwill, leading to a significant stock price decline on February 25, 2025, after the company announced delays in its earnings release and annual report due to an identified error in revenue recognition and a potential non-cash impairment charge. Investors who purchased Maravai securities during the Class Period (August 7, 2024, through February 24, 2025) are encouraged to contact the law firm to discuss their rights.
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Maravai Lifesciences Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRVI
Rosen Law Firm is reminding investors of Maravai Lifesciences Holdings, Inc. (NASDAQ:MRVI) that the lead plaintiff deadline for a securities class action lawsuit is May 5, 2025. The lawsuit alleges that Maravai made false and misleading statements regarding its financial reporting and goodwill. Investors who purchased Maravai securities between August 7, 2024, and February 24, 2025, are encouraged to secure counsel.
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Maravai LifeSciences Holdings, Inc. (MRVI) Shareholders
Levi & Korsinsky has filed a securities class action lawsuit against Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) on behalf of shareholders who suffered losses due to alleged securities fraud between August 7, 2024, and February 24, 2025. The lawsuit claims that Maravai made false statements and concealed issues regarding its internal controls over financial reporting, leading to inaccurate revenue recognition and an overstatement of goodwill. Shareholders affected during this period are encouraged to seek information on potential recovery.
Maravai LifeSciences Reports Third Quarter 2025 Financial Results
Maravai LifeSciences (NASDAQ: MRVI) announced its third quarter 2025 financial results, reporting revenue of $41.6 million, a net loss of $(45.1) million, and Adjusted EBITDA of $(10.8) million. Despite a decline in Nucleic Acid Production revenue due to fewer high-volume CleanCap orders, the company projects full-year 2025 revenue of approximately $185.0 million and anticipates double-digit sequential revenue growth for TriLink in Q4 2025. The company leadership expressed confidence in their restructuring initiatives to deliver attractive financial results for the remainder of 2025 and 2026.
MARAVAI INVESTIGATION REMINDER: Bragar Eagel & Squire, P.C.
Bragar Eagel & Squire, P.C. is continuing its investigation into Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) on behalf of long-term stockholders. This follows a class action complaint alleging that Maravai made materially false or misleading statements and failed to disclose critical information regarding revenue recognition errors and internal control weaknesses. The investigation focuses on whether Maravai's board of directors breached their fiduciary duties, especially after the company postponed its 2024 earnings release and reported a material weakness in internal controls over revenue recognition, causing a significant stock drop.
Levi & Korsinsky Notifies Shareholders of Maravai LifeSciences Holdings, Inc.(MRVI) of a Class Action Lawsuit and an Upcoming Deadline
Levi & Korsinsky has notified shareholders of Maravai LifeSciences Holdings, Inc. (MRVI) about a class action lawsuit. This notice highlights an upcoming deadline for shareholders to potentially participate in the lawsuit. The specific details of the lawsuit and the deadline are not provided in this snippet.
MRVI Investors Have Opportunity to Lead Maravai LifeSciences Holdings, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. Investors who purchased MRVI securities between November 10, 2020, and May 10, 2022, have until October 24, 2023, to apply to be lead plaintiff. The lawsuit alleges that Maravai made false and misleading statements regarding its business, operations, and prospects, and failed to disclose that its COVID-19 revenue was unsustainable and would decline.
ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Maravai Lifesciences Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MRVI
This article from Rosen Law Firm encourages investors in Maravai Lifesciences Holdings, Inc. (MRVI) to secure legal counsel due to an approaching deadline in a securities class action lawsuit. Investors who purchased MRVI securities between May 6, 2021, and November 10, 2023, may be eligible to join the class action. The lawsuit alleges that Maravai made materially false and misleading statements regarding its business, operations, and prospects.
The Gross Law Firm Notifies Shareholders of Maravai LifeSciences Holdings, Inc. (MRVI) of a Class Action Lawsuit and an Upcoming Deadline
The Gross Law Firm has issued a notice to shareholders of Maravai LifeSciences Holdings, Inc. (MRVI) regarding a class action lawsuit. The lawsuit alleges that Maravai LifeSciences Holdings, Inc. issued materially false and misleading statements concerning its revenue recognition and goodwill. Shareholders who purchased MRVI shares between August 7, 2024, and February 24, 2025, are encouraged to contact the firm by the May 5, 2025 deadline to potentially be appointed as lead plaintiff.
Maravai LifeSciences Holdings, Inc. Class Action: The Gross Law Firm Reminds Maravai LifeSciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 5, 2025 – MRVI
The Gross Law Firm is reminding investors of Maravai LifeSciences Holdings, Inc. (MRVI) about a pending class action lawsuit. Investors who purchased MRVI securities between November 10, 2022, and May 7, 2024, are encouraged to contact the firm to learn about their rights. The deadline to apply to be a lead plaintiff in the lawsuit is May 5, 2025.
MARAVAI (MRVI) INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Investigation into Maravai LifeSciences Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) on behalf of long-term stockholders following a class action complaint filed on March 3, 2025. The investigation stems from Maravai postponing its fiscal 2024 earnings and delaying its 10-K filing due to an identified error in revenue recognition of approximately $3.9 million, a material weakness in internal controls, and a potential non-cash impairment charge related to an acquisition. This news caused Maravai's share price to drop 21.70% to $3.14 on February 25, 2025.
MARAVAI LIFESCIENCES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Maravai LifeSciences Holdings, Inc. - MRVI
Kahn Swick & Foti, LLC (KSF), led by former Louisiana Attorney General Charles C. Foti, Jr., has launched an investigation into Maravai LifeSciences Holdings, Inc. (NasdaqGS: MRVI). This investigation follows Maravai's disclosure of delayed annual report filing due to a revenue recognition error and potential impairment charge, which led to an ongoing securities class action lawsuit against the company and its executives. KSF is examining whether Maravai's officers and directors breached their fiduciary duties or violated laws, inviting long-term shareholders to contact them regarding their legal rights.
Maravai LifeSciences Holdings, Inc. (MRVI) Faces Securities Class Action After Delaying Q4 and FY 2024 Earnings Release, Admitting to Improper Revenue Recognition – Hagens Berman
Hagens Berman has announced a securities class action lawsuit against Maravai LifeSciences Holdings, Inc. (MRVI) due to the company's delayed Q4 and FY 2024 earnings report and admission of improper revenue recognition. This revelation led to a significant 23% drop in Maravai's stock price. Investors who suffered losses are encouraged to contact Hagens Berman for more information on the lawsuit and their potential claims.
Maravai LifeSciences Announces Organizational Restructuring and Cost Reduction Initiatives Aiming for $50 Million in Annual Savings | MRVI Stock News
Maravai LifeSciences announced an organizational restructuring and cost reduction initiatives targeting over $50 million in annual savings after reporting a 31.7% year-over-year revenue decline in Q2 2025. The company, which saw a 5% increase in its base business revenue, expects to achieve positive adjusted EBITDA and free cash flow by the second half of 2026. Leadership changes include Bernd Brust as CEO and Raj Asarpota as CFO, as Maravai aims to realign its cost structure and minimize operational disruption.
MRVI Stock Drop: What Investors Should Know
Maravai LifeSciences Holdings Inc. (MRVI) stock dropped significantly by -7.56% on March 19, 2025, amidst multiple class action lawsuits alleging securities fraud, false financial reporting, and inadequate internal controls. The company is facing scrutiny over overstated goodwill, inaccurate revenue recognition, and a Q4 adjusted loss of $0.06 per diluted share. Despite substantial liquidity and total assets, legal challenges and troubling financial signals are creating uncertainty and a cautious sentiment among investors, with one analyst advising a level-headed trading strategy over emotional reactions.
Maravai LifeSciences Reports Second Quarter 2025 Financial Results
Maravai LifeSciences reported its second quarter 2025 financial results, showing a 31.7% decrease in total revenue year-over-year, primarily due to lower CleanCap orders. The company announced a major organizational restructuring and cost reduction plan targeting over $50 million in annualized savings and appointed a new CEO and CFO to drive innovation and improve financial performance. Maravai expects a reduction in net loss, positive Adjusted EBITDA, and positive free cash flow by the second half of 2026, while withdrawing its full-year 2025 revenue guidance during its business review.
Maravai LifeSciences Reports Second Quarter 2025 Financial Results
Maravai LifeSciences (NASDAQ: MRVI) reported its second-quarter 2025 financial results, with revenue of $47.4 million, a net loss of $(69.8) million, and adjusted EBITDA of $(10.4) million. The company announced an organizational restructuring and cost reduction initiatives aimed at over $50 million in annualized savings, and it expects a net loss reduction, positive Adjusted EBITDA, and positive free cash flow by the second half of 2026. Maravai also appointed Bernd Brust as CEO and Raj Asarpota as CFO to drive innovation and performance.
Maravai LifeSciences Appoints Bernd Brust as CEO, Succeeding Trey Martin
Maravai LifeSciences has appointed Bernd Brust as its new CEO and a board member, replacing William "Trey" Martin III. Brust brings over 30 years of experience in the life sciences industry, with a focus on driving innovation and financial performance. The company aims to expand its market leadership in mRNA and bioprocess impurity detection under Brust's leadership, while reaffirming its commitment to customer-centric solutions.
Levi & Korsinsky Reminds Maravai LifeSciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 5, 2025 - MRVI
Levi & Korsinsky LLP reminds investors of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) about a pending class action lawsuit with a lead plaintiff deadline of May 5, 2025. The lawsuit alleges securities fraud due to misstatements and concealment regarding Maravai's internal controls, revenue recognition, and overstated goodwill between August 7, 2024, and February 24, 2025. Shareholders who suffered losses during this period are encouraged to seek information about their potential recovery rights.
MRVI Investors Have Opportunity to Lead Maravai LifeSciences Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm is reminding investors of a class action lawsuit against Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) for alleged securities fraud. Investors who purchased the company's securities between August 7, 2024, and February 24, 2025, are encouraged to contact the firm before May 5, 2025, to discuss their rights and participate in the lawsuit. The complaint alleges that Maravai made false and misleading statements, failed to maintain adequate internal controls, improperly recognized revenue, and overstated its goodwill.
MRVI Investors Have Opportunity to Lead Maravai LifeSciences Holdings, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm has announced a class action lawsuit against Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) for alleged securities fraud, encouraging investors who purchased shares between August 7, 2024, and February 24, 2025, to contact the firm by May 5, 2025. The lawsuit claims Maravai made false and misleading statements, failed to maintain adequate internal controls, improperly recognized revenue, and overstated its goodwill, leading to investor losses.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Maravai LifeSciences Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines - MRVI
Pomerantz LLP has filed a class action lawsuit against Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) on behalf of investors who suffered losses. The lawsuit stems from Maravai's announcement of postponing its fiscal 2024 earnings release and delaying its annual report due to an identified error in revenue recognition and a material weakness in internal controls, which caused the stock price to drop significantly. Investors have until May 5, 2025, to apply to be appointed as Lead Plaintiff.
May 5, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against MRVI
Levi & Korsinsky LLP has announced a May 5, 2025, deadline for shareholders to join a class action lawsuit against Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI). The lawsuit aims to recover losses for shareholders who were allegedly affected by securities fraud concerning inaccurate revenue recognition and overstated goodwill between August 7, 2024, and February 24, 2025. Shareholders who suffered losses are encouraged to contact the firm to learn about their rights to recovery.
The Gross Law Firm Notifies Maravai LifeSciences Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MRVI
The Gross Law Firm has issued a notice to shareholders of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) regarding a class action lawsuit. Investors who purchased shares between August 7, 2024, and February 24, 2025, are encouraged to contact the firm, as the deadline to seek lead plaintiff appointment is May 5, 2025. The lawsuit alleges that Maravai made materially false and/or misleading statements, particularly regarding its revenue recognition, overstating goodwill during fiscal 2024.
Maravai LifeSciences (MRVI) Reports Weak Q4, Faces Investor Class Action – Hagens Berman
Maravai LifeSciences (MRVI) reported disappointing Q4 2024 earnings, missing analyst expectations and leading to a significant price target cut by Stifel. The company is also facing a securities class action lawsuit alleging improper accounting related to revenue recognition and an overstatement of goodwill. Hagens Berman is investigating these claims, encouraging investors with losses to contact the firm before the May 5th deadline, and highlighting material weaknesses in Maravai's internal controls.
MRVI Deadline in 4 Days: Kessler Topaz Meltzer & Check, LLP Reminds Maravai LifeSciences Holdings, Inc. (MRVI) Investors of Filing Deadline in Class Action Lawsuit
Kessler Topaz Meltzer & Check, LLP is reminding investors of Maravai LifeSciences Holdings, Inc. (MRVI) that the lead plaintiff deadline in a securities class action lawsuit is May 5, 2025. The lawsuit alleges that Maravai made materially false and misleading statements about its revenue recognition and goodwill between August 7, 2024, and February 24, 2025. Investors who suffered losses are encouraged to contact the firm to learn more about seeking lead plaintiff appointment.
Lost Money on Maravai LifeSciences Holdings, Inc.(MRVI)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
The Gross Law Firm has issued a notice to shareholders of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) to join a class action lawsuit. This suit alleges that Maravai made false or misleading statements regarding its revenue recognition, overstated goodwill, and lacked adequate internal controls, leading to artificially inflated stock prices. Shareholders who purchased MRVI shares between August 7, 2024, and February 24, 2025, are encouraged to register for the class action before the May 5, 2025, deadline to seek lead plaintiff appointment.
Levi & Korsinsky Reminds Maravai LifeSciences Holdings, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 5, 2025 - MRVI
Levi & Korsinsky LLP has reminded investors of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) about a pending class action lawsuit with a lead plaintiff deadline of May 5, 2025. The lawsuit alleges that Maravai made false statements and/or concealed issues related to inadequate internal controls over financial reporting, inaccurate revenue recognition, and overstated goodwill between August 7, 2024, and February 24, 2025. Investors who suffered losses during this period are encouraged to seek more information about their rights.
Class Action Filed Against Maravai LifeSciences Holdings, Inc. (MRVI) Seeking Recovery for Investors - Contact Levi & Korsinsky
A class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. (MRVI) on behalf of investors who suffered losses between August 7, 2024, and February 24, 2025. The lawsuit alleges that Maravai made false statements concerning its internal controls over financial reporting, revenue recognition, and overstating goodwill. Investors are encouraged to contact Levi & Korsinsky, LLP to learn about their rights to potentially recover losses.
Levi & Korsinsky Reminds Maravai LifeSciences Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 5, 2025 - MRVI
Levi & Korsinsky LLP announced a pending class action lawsuit against Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) for alleged securities fraud from August 7, 2024, to February 24, 2025. The lawsuit claims Maravai lacked adequate internal controls, inaccurately recognized revenue, and overstated goodwill, leading to misleading statements about the company's prospects. Investors who suffered losses are encouraged to seek information on recovering their investments before the May 5, 2025, lead plaintiff deadline.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 5, 2025 in Maravai LifeSciences Lawsuit - MRVI
Levi & Korsinsky LLP is reminding shareholders of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) about a lead plaintiff deadline of May 5, 2025, for a class action securities lawsuit. The lawsuit alleges that Maravai made false statements and concealed issues regarding its internal controls, revenue recognition, and overstated goodwill between August 7, 2024, and February 24, 2025. Shareholders who suffered losses during this period are encouraged to seek information about their rights.
Investors who lost money on Maravai LifeSciences Holdings, Inc.(MRVI) should contact The Gross Law Firm about pending Class Action - MRVI
The Gross Law Firm has issued a notice to shareholders of Maravai LifeSciences Holdings, Inc. (MRVI) regarding a pending class action lawsuit. The lawsuit alleges that Maravai made false and misleading statements and failed to disclose issues with revenue recognition and an overstatement of goodwill between August 7, 2024, and February 24, 2025. Shareholders who purchased shares during this period and suffered losses are encouraged to contact the firm by the May 5, 2025, deadline to potentially be appointed as lead plaintiff.
Fat Pitch Financials - Maravai LifeSciences Holdings, Inc. (MRVI) Investors: May 5, 2025 Filing Deadline in Securities Class Action - Contact Kessler Topaz Meltzer & Check, LLP
Kessler Topaz Meltzer & Check, LLP is informing investors of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) about a securities class action lawsuit with a lead plaintiff deadline of May 5, 2025. The lawsuit alleges that Maravai made materially false or misleading statements and failed to disclose adequate internal controls, inaccurate revenue recognition, and overstated goodwill between August 7, 2024, and February 24, 2025. Investors who suffered losses are encouraged to contact the firm for more information regarding their potential to act as lead plaintiff.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Maravai LifeSciences Holidngs, Inc. of Class Action Lawsuit and Upcoming Deadlines - MRVI
Pomerantz LLP has announced a class action lawsuit against Maravai LifeSciences Holdings, Inc. (MRVI) following an identified error in revenue recognition and a material weakness in internal controls, which caused the company to postpone its 2024 earnings release and delay filing its annual report. Investors who purchased Maravai securities during the Class Period are encouraged to contact the firm by May 5, 2025, to seek appointment as Lead Plaintiff. The news of the revenue error and control weakness led to a significant drop in Maravai's stock price.
Class Action Filed Against Maravai LifeSciences Holdings, Inc. (MRVI) - May 5, 2025 Deadline to Join - Contact Levi & Korsinsky
Levi & Korsinsky, LLP has filed a class action securities lawsuit against Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) on behalf of investors who suffered losses between August 7, 2024, and February 24, 2025. The lawsuit alleges that Maravai made false statements concerning its financial reporting, including inadequate internal controls over revenue recognition and overstated goodwill. Investors have until May 5, 2025, to request to be appointed as lead plaintiff.
Levi & Korsinsky Notifies Shareholders of Maravai LifeSciences Holdings, Inc. (MRVI) of a Class Action Lawsuit and an Upcoming Deadline
Levi & Korsinsky has informed shareholders of Maravai LifeSciences Holdings, Inc. (MRVI) about a class action lawsuit filed against the company. The lawsuit alleges securities fraud between August 7, 2024, and February 24, 2025, due to issues with internal controls over revenue recognition and overstated goodwill. Shareholders who experienced losses during this period are encouraged to seek information on potential recovery.
MRVI INVESTOR ALERT: Kirby McInerney LLP Reminds Maravai Lifesciences Holdings, Inc. Investors of Looming Lead Plaintiff Deadline in Class Action Lawsuit
Kirby McInerney LLP is reminding investors of Maravai Lifesciences Holdings, Inc. (NASDAQ: MRVI) about a looming lead plaintiff deadline of May 5, 2025, in a federal securities class action lawsuit. The lawsuit alleges that Maravai made misleading statements regarding its revenue recognition practices and internal controls, leading to a significant drop in stock price. Investors who purchased Maravai securities between August 7, 2024, and February 24, 2025, are encouraged to contact the law firm to discuss their rights.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Maravai LifeSciences Holidngs, Inc. of Class Action Lawsuit and Upcoming Deadlines - MRVI
Pomerantz LLP has filed a class action lawsuit against Maravai LifeSciences Holdings, Inc. (MRVI) following the company's disclosure of revenue recognition errors and material weaknesses in internal controls. The lawsuit stems from an announcement that $3.9 million in revenue was improperly recorded, leading to a 21.7% drop in stock price; investors have until May 5, 2025, to seek lead plaintiff status.
MRVI Investors Have Opportunity to Lead Maravai Lifesciences Holdings, Inc. Securities Fraud Lawsuit
The Rosen Law Firm is reminding purchasers of Maravai Lifesciences Holdings, Inc. securities, bought between August 7, 2024, and February 24, 2025, of an upcoming lead plaintiff deadline on May 5, 2025. Investors are encouraged to join a class action lawsuit alleging securities fraud due to misstatements regarding revenue recognition and an overstatement of goodwill. The firm, known for its success in securities class actions, emphasizes the importance of selecting qualified counsel.
Class Action Filed Against Maravai LifeSciences Holdings, Inc. (MRVI) Seeking Recovery for Investors - Contact Levi & Korsinsky
A class action lawsuit has been filed against Maravai LifeSciences Holdings, Inc. (MRVI) alleging securities fraud between August 7, 2024, and February 24, 2025. The lawsuit claims Maravai lacked adequate internal controls over financial reporting, inaccurately recognized revenue, and overstated goodwill, leading to misleading statements about the company's business. Investors who suffered losses during this period are encouraged to contact Levi & Korsinsky, LLP for potential recovery.
Levi & Korsinsky Notifies Shareholders of Maravai LifeSciences Holdings, Inc. (MRVI) of a Class Action Lawsuit and an Upcoming Deadline
Levi & Korsinsky LLP has announced a class action lawsuit against Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) for alleged securities fraud between August 7, 2024, and February 24, 2025. The lawsuit claims that Maravai made false statements regarding its internal controls over financial reporting, revenue recognition, and goodwill, leading to overstated financial results. Shareholders who suffered losses during this period are encouraged to seek information about their rights to recovery through the firm.
Levi & Korsinsky Notifies Maravai LifeSciences Holdings, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - MRVI
Levi & Korsinsky, LLP has filed a class action securities lawsuit against Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) on behalf of investors who suffered losses due to alleged securities fraud between August 7, 2024, and February 24, 2025. The lawsuit claims that Maravai made false statements and concealed issues regarding revenue recognition, overstated goodwill, and misleading business prospects. Investors have until May 5, 2025, to request to be appointed as lead plaintiff in the case.
MRVI Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Maravai LifeSciences Holdings, Inc. (MRVI)
Kessler Topaz Meltzer & Check, LLP has filed a securities class action lawsuit against Maravai LifeSciences Holdings, Inc. (MRVI) on behalf of investors who purchased securities between August 7, 2024, and February 24, 2025. The lawsuit alleges that Maravai made false and misleading statements regarding its revenue recognition and overstated goodwill. Investors have until May 5, 2025, to seek appointment as lead plaintiff.
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 5, 2025 in Maravai LifeSciences Holdings, Inc. Lawsuit – MRVI
The Gross Law Firm is reminding shareholders of Maravai LifeSciences Holdings, Inc. (MRVI) that a lead plaintiff deadline of May 5, 2025, has been set for a class action lawsuit. The lawsuit alleges that Maravai issued false and/or misleading statements regarding its financial reporting and goodwill during the class period of August 7, 2024, to February 24, 2025. Shareholders who purchased shares during this period are encouraged to contact the firm to learn about their options.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Maravai LifeSciences Holidngs, Inc. of Class Action Lawsuit and Upcoming Deadlines - MRVI
Pomerantz LLP has filed a class action lawsuit against Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) following the company's announcement of postponed fiscal 2024 earnings and a delayed 10-K filing due to an error in revenue recognition and a material weakness in internal controls. Investors who purchased Maravai securities during the Class Period are encouraged to contact Pomerantz LLP to inquire about joining the lawsuit, with a lead plaintiff deadline of May 5, 2025. The company's stock price fell significantly after the disclosure of the financial issues.
